Advertisement

Pharmaceutisch Weekblad

, Volume 4, Issue 5, pp 154–158 | Cite as

Angiotensin converting enzyme inhibitors

  • W. Soudijn
Medicinal Chemistry Congress

Abstract

Inhibition of angiotensin converting enzyme (scace) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally activeace inhibitor and the structure-activity relationship of captopril analogues are described. Some side effects of captopril were attributed to the presence of an SH-group in the molecule. This led to the development of a series of non-mercaptoace inhibitors derived from captopril. One of them, enalapril, a potentace inhibitor with a long duration of antihypertensive action, is now tested in clinical trials.

Keywords

Public Health Hypertension Clinical Trial Internal Medicine Angiotensin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antonaccio, M.J. (1982)Ann. Rev. Pharmacol. Toxicol. 22, 57–87.Google Scholar
  2. Brunner, D.B., G. Desponds, J. Biollaz, I. Keller, F. Ferber, H. Gavras, H.R. Brunner andJ.L. Schelling (1981)Brit. J. Clin. Pharmacol, 11, 461–467.Google Scholar
  3. Gavras, H., B. Waeber, I. Gavras, J. Biollaz, H.R. Brunner andR.O. Davies (1981)Lancet II, 543–546.Google Scholar
  4. Petrillo, E.W., andA. Ondetti (1982)Med. Res. Rev. 2, 1–41.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1982

Authors and Affiliations

  • W. Soudijn
    • 1
  1. 1.Dept. of Pharmaceutical ChemistryUniversity of AmsterdamTV AmsterdamThe Netherlands

Personalised recommendations